Canagliflozin in Postprandial Hyperinsulinemic Hypoglycemia (CANA-PHH-RYGB)
NCT04720859
·
clinicaltrials.gov ↗
NA
Phase
UNKNOWN
Status
40
Enrollment
OTHER
Sponsor class
Conditions
Postprandial Hypoglycemia
Interventions
DRUG:
Canagliflozin 300 MG Oral Tablet
Sponsor
Hospital Universitari Vall d'Hebron Research Institute